NasdaqGS - Delayed Quote USD

Puma Biotechnology, Inc. (PBYI)

5.02 +0.14 (+2.87%)
At close: April 26 at 4:00 PM EDT
5.12 +0.10 (+1.99%)
After hours: April 26 at 7:34 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
235,637.00
235,637.00
228,031.00
253,155.00
225,110.00
Cost of Revenue
62,682.00
62,682.00
55,093.00
63,701.00
39,374.00
Gross Profit
172,955.00
172,955.00
172,938.00
189,454.00
185,736.00
Operating Expense
139,690.00
139,690.00
142,218.00
188,164.00
216,138.00
Operating Income
33,265.00
33,265.00
30,720.00
1,290.00
-30,402.00
Net Non Operating Interest Income Expense
-10,725.00
-10,725.00
-10,779.00
-12,647.00
-13,557.00
Other Income Expense
134.00
134.00
-19,484.00
-17,445.00
-15,829.00
Pretax Income
22,674.00
22,674.00
457.00
-28,802.00
-59,788.00
Tax Provision
1,083.00
1,083.00
455.00
324.00
207.00
Net Income Common Stockholders
21,591.00
21,591.00
2.00
-29,126.00
-59,995.00
Diluted NI Available to Com Stockholders
21,591.00
21,591.00
2.00
-29,126.00
-59,995.00
Basic EPS
0.46
0.46
0.00
-0.72
-1.52
Diluted EPS
0.45
0.45
0.00
-0.72
-1.52
Basic Average Shares
47,134.33
47,134.33
44,674.50
40,638.85
39,576.11
Diluted Average Shares
47,550.85
47,550.85
44,930.00
40,638.85
39,576.11
Total Operating Income as Reported
32,640.00
32,640.00
23,720.00
1,290.00
-30,402.00
Total Expenses
202,372.00
202,372.00
197,311.00
251,865.00
255,512.00
Net Income from Continuing & Discontinued Operation
21,591.00
21,591.00
2.00
-29,126.00
-59,995.00
Normalized Income
22,186.15
22,186.15
15,372.24
-16,177.99
-48,171.92
Interest Income
2,605.00
2,605.00
813.00
160.00
489.00
Interest Expense
13,330.00
13,330.00
11,592.00
12,807.00
14,046.00
Net Interest Income
-10,725.00
-10,725.00
-10,779.00
-12,647.00
-13,557.00
EBIT
36,004.00
36,004.00
12,049.00
-15,995.00
-45,742.00
EBITDA
47,523.00
47,523.00
21,889.00
-4,690.00
-35,709.00
Reconciled Cost of Revenue
62,682.00
62,682.00
55,093.00
63,701.00
39,374.00
Reconciled Depreciation
11,519.00
11,519.00
9,840.00
11,305.00
10,033.00
Net Income from Continuing Operation Net Minority Interest
21,591.00
21,591.00
2.00
-29,126.00
-59,995.00
Total Unusual Items Excluding Goodwill
-625.00
-625.00
-19,456.00
-17,737.00
-16,196.00
Total Unusual Items
-625.00
-625.00
-19,456.00
-17,737.00
-16,196.00
Normalized EBITDA
48,148.00
48,148.00
41,345.00
13,047.00
-19,513.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-29.85
-29.85
-4,085.76
-4,788.99
-4,372.92
12/31/2020 - 4/24/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
VYGR Voyager Therapeutics, Inc.
7.62
+2.70%
 
VTGN Vistagen Therapeutics, Inc.
4.7500
+1.06%
 
ADVM Adverum Biotechnologies, Inc.
9.19
-2.13%
 
KPTI Karyopharm Therapeutics Inc.
1.0600
0.00%
 
PTCT PTC Therapeutics, Inc.
28.57
+12.08%
 
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
 
HRMY Harmony Biosciences Holdings, Inc.
29.32
+1.35%
 
BLUE bluebird bio, Inc.
0.9228
+1.13%
 
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%